Author: admin

Continue Reading

  • Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial

    Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial

    Competing interests

    S.B. has received honoraria for consulting and/or advisory board work from AbbVie, AstraZeneca, BioNTech, Eisai, Gilead, GlaxoSmithKline, Grey Wolf Therapeutics, Immunogen, Incyte, ITM…

    Continue Reading

  • PARP inhibitor-induced anti-tumour chemokine response is suppressed by dipeptidyl peptidase 4 (DPP4) in ovarian cancer

    PARP inhibitor-induced anti-tumour chemokine response is suppressed by dipeptidyl peptidase 4 (DPP4) in ovarian cancer

  • Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I, et al. The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann Oncol. 2020;31:1148–59.

    Article 
    CAS 
    PubMed 

    Google…

  • Continue Reading

  • Author Correction: Global implementation and evaluation of atrial fibrillation screening in the past two decades – a narrative review

    Continue Reading

  • Astronomy as a strategic driver for sustainable development

    Astronomy as a strategic driver for sustainable development

    Astronomy as a strategic driver for sustainable development

    Continue Reading

  • Synthesis, characterization and cytotoxic evaluation of metal complexes derived from new N′-(2-cyanoacetyl)isonicotinohydrazide

    Synthesis, characterization and cytotoxic evaluation of metal complexes derived from new N′-(2-cyanoacetyl)isonicotinohydrazide

    The N’-(2-cyanoacetyl)isonicotinohydrazide (H2L) elemental analyses indicated that it had C9H8N4O2 formula, whereas its complexes were 1:1 (M: L) stoichiometry and were soluble only in DMF and DMSO. The complexes were non-electrolytic, where…

    Continue Reading